Epidermolysis Bullosa (EB) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033


 Epidermolysis bullosa is an infrequent, often severe genetic disorder characterized by skin, mucosal, or organ fragility, resulting in blistering or erosions, even from minor injuries. Severe forms of the condition can lead to skin issues like blistering, open wounds, and scarring and affect other body systems, such as the gastrointestinal, cardiovascular, genitourinary, ocular, and oral systems, and raise the risk of early mortality. Various gene mutations affecting proteins responsible for skin integrity encompass keratins (KRT5, KRT14), laminin-332 (LAMA3, LAMB3, LAMC2), dystonin epithelial isoform (DST), and collagen types VII and XVII (COL7A1, COL17A1). These mutations yield different disease types and subtypes categorized by the location of skin cleavage, each with distinct presentations. The primary forms include epidermolysis bullosa simplex (making up about 70% of cases), dystrophic epidermolysis bullosa (25%), junctional epidermolysis bullosa (5%), and Kindler syndrome. Yet, the first three subtypes account for nearly 99% of affected individuals. Currently, there are no approved treatments for epidermolysis bullosa, and the primary focus is preventing blister formation, managing wounds, alleviating pain, and promptly addressing extracutaneous complications.

·       According to data from the National Epidermolysis Bullosa Registry, the estimated prevalence of epidermolysis bullosa in the United States is 11.1 cases per one million live births, with an incidence rate of one in every 51,000 live births


Thelansis’s “Epidermolysis Bullosa (EB) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Epidermolysis Bullosa (EB) treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

 

KOLs insights of Epidermolysis Bullosa (EB) across 8 MM market from the centre of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs.

Epidermolysis Bullosa (EB) Market Forecast Patient Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs with sourcing, Market Event, and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden, and pricing scenario, Summary, and Insights.

Thelansis Competitive Intelligence (CI) practice has been established based on a deep understanding of the pharma/biotech business environment to provide an optimized support system to all levels of the decision-making process. It enables business leaders in forward-thinking and proactive decision-making. Thelansis supports scientific and commercial teams in seamless CI support by creating an AI/ ML-based technology-driven platform that manages the data flow from primary and secondary sources.

Read more: Epidermolysis Bullosa (EB) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033

Epidermolysis bullosa is an infrequent, often severe genetic disorder characterized by skin, mucosal, or organ fragility, resulting in blistering or erosions, even from minor injuries. Severe forms of the condition can lead to skin issues like blistering, open wounds, and scarring and affect other body systems, such as the gastrointestinal, cardiovascular, genitourinary, ocular, and oral systems, and raise the risk of early mortality. Various gene mutations affecting proteins responsible for skin integrity encompass keratins (KRT5, KRT14), laminin-332 (LAMA3, LAMB3, LAMC2), dystonin epithelial isoform (DST), and collagen types VII and XVII (COL7A1, COL17A1). These mutations yield different disease types and subtypes categorized by the location of skin cleavage, each with distinct presentations. The primary forms include epidermolysis bullosa simplex (making up about 70% of cases), dystrophic epidermolysis bullosa (25%), junctional epidermolysis bullosa (5%), and Kindler syndrome. Yet, the first three subtypes account for nearly 99% of affected individuals. Currently, there are no approved treatments for epidermolysis bullosa, and the primary focus is preventing blister formation, managing wounds, alleviating pain, and promptly addressing extracutaneous complications.

·       According to data from the National Epidermolysis Bullosa Registry, the estimated prevalence of epidermolysis bullosa in the United States is 11.1 cases per one million live births, with an incidence rate of one in every 51,000 live births


Thelansis’s “Epidermolysis Bullosa (EB) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Epidermolysis Bullosa (EB) treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

 

KOLs insights of Epidermolysis Bullosa (EB) across 8 MM market from the centre of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs.

Epidermolysis Bullosa (EB) Market Forecast Patient Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs with sourcing, Market Event, and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden, and pricing scenario, Summary, and Insights.

Thelansis Competitive Intelligence (CI) practice has been established based on a deep understanding of the pharma/biotech business environment to provide an optimized support system to all levels of the decision-making process. It enables business leaders in forward-thinking and proactive decision-making. Thelansis supports scientific and commercial teams in seamless CI support by creating an AI/ ML-based technology-driven platform that manages the data flow from primary and secondary sources.

Read more: Epidermolysis Bullosa (EB) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033

Comments

Post a Comment

Popular posts from this blog

Acne Vulgaris – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2022 To 2032

Image
  Acne vulgaris, a prevalent pilosebaceous unit inflammatory skin disorder, follows a persistent course. Typically presenting as papules, pustules, or nodules, it primarily occurs on the face but can also impact the upper arms, trunk, and back. The development of acne results from the sebaceous glands' heightened sensitivity to normal androgen levels, aggravated by Cutibacterium acnes (formerly known as Propionibacterium acnes), a bacterial species that triggers inflammation. The pathogenesis of acne vulgaris involves a complex interplay of factors such as the activation of sebaceous glands by androgens, imbalances in the pilosebaceous follicle microbiome, and cellular immune responses. Genetic predisposition and dietary influences also contribute to the condition's onset and progression. The initial stage is the micro-comedo, a small plug primarily composed of corneocytes in the lower follicular infundibulum. Microcomedones evolve into various acne lesions, including closed co...
Read more

Herpes Simplex Virus (HSV) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033

Image
 Herpes simplex virus (HSV) causes an infection that affects the external genitalia, anal region, mucosal surfaces, and skin in other body parts. Herpes simplex virus is a ubiquitous, host-adapted pathogen that causes various disease states. There are two types of HSV with two distinct DNA viruses, type 1 (HSV-1) and type 2 (HSV-2). Both the types are closely related but differ epidemiologically. HSV-1 is traditionally associated with orofacial disease by affecting the mouth and lips with fever blisters and cold sores, whereas HSV-2 is associated traditionally with genital disease infecting genitals and rectum area with sores and is classified as STD (sexually transmitted disease). As HSV-1 is associated with genital infections more often than HSV-2, lesion location is not necessarily of viral type. HSV can spread through direct contact. Almost 80% of Herpes simplex infections are asymptomatic, while symptomatic infections can be characterized by significant morbidity and recurrenc...
Read more

HR+/HER2- Breast Cancer – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033

Image
Thelansis’s “HR+/HER2- Breast Cancer Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential HR+/HER2- Breast Cancer treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China). KOLs insights of HR+/HER2- Breast Cancer across 8 MM market from the centre of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs. HR+/HER2- Breast Cancer Market Forecast Patient Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs with sourcing, Market Event, and Product Event, Country specific Forecast Model,...
Read more